Investment
Features
FeesSafety
Academy
More
Pluang+

Compare UBC Medical Indonesia Tbk. (LABS) vs Zyrexindo Mandiri Buana Tbk. (ZYRX) Price & Performance

UBC Medical Indonesia Tbk.Trade
Zyrexindo Mandiri Buana Tbk.Trade

Price performance (Past 24H)

Key statistics

UBC Medical Indonesia Tbk. vs Zyrexindo Mandiri Buana Tbk. — how do they compare? UBC Medical Indonesia Tbk. trades at Rp174 (market cap 691.25B, 635.5K 24h volume), while Zyrexindo Mandiri Buana Tbk. trades at Rp127 (market cap 172B, 315.2K 24h volume). The key difference: UBC Medical Indonesia Tbk. is far larger — about 4× Zyrexindo Mandiri Buana Tbk.'s market cap, and UBC Medical Indonesia Tbk. is more actively traded (635.5K versus 315.2K). Which is the better fit depends on your goals.

LABSZYRX
Market Cap
691.25B172B
Volume
635.5K315.2K
Lot
6.36K3.15K
Turnover
110.15M40.04M
Average Price
173.33127.02
Value
110.15M40.04M
Indicative Equilibrium Price
174127
Indicative Equilibrium Volume
50400

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

LABS
View details
ZYRX
View details

About UBC Medical Indonesia Tbk.

PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.

Read more on LABS

About Zyrexindo Mandiri Buana Tbk.

PT Zyrexindo Mandiri Buana Tbk (the Company) is a limited liability company established in Indonesia based on Notarial Deed No. 43 of Jimmy Simanungkalit, S.H., on May 14, 1996. The Company commenced its commercial operations in 1996. The majority shareholder of the Company is Timothy Siddik

Read more on ZYRX